Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02737033

Enrollment

Registered

2016-04-13

Start date

2016-04-30

Completion date

2021-03-31

Last updated

2019-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

ADHD, Adults, Treatment, Rhodiola

Brief summary

This study evaluates the use of Rhodiola rosea in the attention of adults with Attention Deficit/Hyperactivity Disorder (ADHD). Half of participants will receive Rhodiola rosea 800mg, while the other half will receive 800mg of placebo.

Detailed description

The evaluation of new therapies in adults with Attention Deficit/Hyperactivity Disorder (ADHD) may be clinically useful. Rhodiola rosea is an herbal medicine used for centuries in various medical conditions. Many randomized controlled trials have evaluated its usefulness in stress and fatigue. There were benefits in attention in some of these studies. Mild side effects and beneficial antioxidant properties make reasonable an assessment of its potential benefits in adults with ADHD. To our knowledge, Rhodiola rosea has never been studied in adults with ADHD.

Interventions

DRUGRhodiola

Rhodiola rosea 800mg

DRUGPlacebo

innocuous pill manufactured to mimic Rhodiola

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Fulfillment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) diagnostic criteria for ADHD in Adults * Intelligence Quotient (IQ) above 70 * Eligibility to Rhodiola rosea

Exclusion criteria

* clinical contraindication to Rhodiola rosea * any unstable chronic illness without proper treatment (hypertension, heart, kidney or liver disease, etc) * any significant neurological disease (delirium, dementia, epilepsy, AIDS, head trauma, multiple sclerosis, stroke, etc) * unstable psychiatric comorbidities requiring immediate treatment (risk of suicide, current Substance Use Disorder, etc.) * pregnant, nursing or absence of reliable contraception * current use of nicotine (\<30 days) * use of anticoagulants * current use of any psychoactive drug (\<30 days) * prior use of stimulants * current or lifetime psychosis * current or lifetime bipolar disorder

Design outcomes

Primary

Measure	Time frame	Description
Change in Stop Signal Task	Baseline and 4 hours	Change from baseline attention 4 hours after a single dose of Rhodiola 800mg or placebo

Secondary

Measure	Time frame	Description
Change in Wechsler Adult Intelligence Scale (WAIS) - Digit Span subtest	Baseline and 4 hours	Change from baseline attention 4 hours after a single dose of Rhodiola 800mg or placebo

Countries

Brazil

Contacts

Primary ContactEugenio Grevet, PhD

ehgrevet@gmail.com55 51 3359-8094

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026